| [1] | Ong VH, Denton CP (2010) Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 22: 264-272. doi:10.1097/BOR.0b013e328337c3d6. PubMed: 20190640.
|
| [2] | Varga J (2012) Etiology and Pathogenesis of Scleroderma. 9 #. ed. pp. 1343-1353.
|
| [3] | Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126: 561-568. PubMed: 1610706.
|
| [4] | Cutolo M, Sulli A, Smith V (2010) Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 6: 578-587. doi:10.1038/nrrheum.2010.104. PubMed: 20703220.
|
| [5] | Abraham D, Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9 Suppl 2: S2. doi:10.1186/ar2228.
|
| [6] | Balbir-Gurman A, Braun-Moscovici Y (2012) Scleroderma - new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol 26: 13-24. doi:10.1016/j.berh.2012.01.011. PubMed: 22424190.
|
| [7] | Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26: 587-595. doi:10.1016/j.it.2005.09.004. PubMed: 16168711.
|
| [8] | Kahaleh MB, LeRoy EC (1999) Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31: 195-214. doi:10.3109/08916939908994064. PubMed: 10739336.
|
| [9] | Del PN, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F et al. (2004) Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50: 1296-1304. doi:10.1002/art.20116. PubMed: 15077314.
|
| [10] | Cerinic MM, Valentini G, Sorano GG, D'Angelo S, Cuomo G et al. (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32: 285-295. doi:10.1053/sarh.2002.50011. PubMed: 12701039.
|
| [11] | Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117: 557-567. doi:10.1172/JCI31139. PubMed: 17332883.
|
| [12] | Deleuran B, Abraham DJ (2007) Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 3: 682-683. doi:10.1038/ncprheum0618. PubMed: 17848933.
|
| [13] | Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H et al. (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43: 2455-2463. doi:10.1002/1529-0131(200011)43:11. PubMed: 11083268.
|
| [14] | Rodríguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martínez-Reyes C et al. (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int 32: 2653-2660. doi:10.1007/s00296-011-2056-y. PubMed: 21789610.
|
| [15] | Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C (2011) Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 13: R166. doi:10.1186/ar3486. PubMed: 21996293.
|
| [16] | Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL et al. (2012) Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum 64: 3726-3735. doi:10.1002/art.34643. PubMed: 22833167.
|
| [17] | Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980). Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581-590.
|
| [18] | Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della RA et al. (2003) European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 62: 901-903. doi:10.1136/ard.62.9.901. PubMed: 12922968.
|
| [19] | Ades EW, Candal FJ, Swerlick RA, George VG, Summers S et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99: 683-690. doi:10.1111/1523-1747.ep12613748. PubMed: 1361507.
|
| [20] | Zepp J, Wu L, Li X (2011) IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 32: 232-239. doi:10.1016/j.it.2011.02.007. PubMed: 21493143.
|
| [21] | Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY et al. (2007) Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 46: 57-64. doi:10.1093/rheumatology/kel159. PubMed: 16772307.
|
| [22] | Roussel L, Houle F, Chan C, Yao Y, Bérubé J et al. (2010) IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 184: 4531-4537. doi:10.4049/jimmunol.0903162. PubMed: 20228195.
|
| [23] | Sakkas LI, Platsoucas CD (2004) Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 50: 1721-1733. doi:10.1002/art.20315. PubMed: 15188347.
|
| [24] | Wells AU, Lorimer S, Majumdar S, Harrison NK, Corrin B et al. (1995) Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 8: 266-271. doi:10.1183/09031936.95.08020266. PubMed: 7758562.
|
| [25] | Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E et al. (2005) Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64: 1233-1235. doi:10.1136/ard.2004.027094. PubMed: 16014686.
|
| [26] | O'Reilly S, Hugle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 51: 1540-1549. doi:10.1093/rheumatology/kes090.
|
| [27] | Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R et al. (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLOS ONE 4: e5903. doi:10.1371/journal.pone.0005903. PubMed: 19536281.
|
| [28] | Yang J, Yang X, Zou H, Chu Y, Li M (2011) Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford) 50: 1366-1372. doi:10.1093/rheumatology/ker116. PubMed: 21489974.
|
| [29] | Abraham D, Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9 Suppl 2: S2. doi:10.1186/ar2228.
|
| [30] | Aggarwal S, Gurney AL (2002) IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71: 1-8. PubMed: 11781375.
|
| [31] | Hashimoto M, Mimori T (2012) Role of Th17 cells and innate immunnity for the induction of autoimmune arthritis. Nihon Rinsho Meneki Gakkai Kaishi 35: 463-469. doi:10.2177/jsci.35.463. PubMed: 23291481.
|
| [32] | Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R et al. (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173-1175. doi:10.1038/nm1651. PubMed: 17828272.
|
| [33] | Yang J, Chu Y, Yang X, Gao D, Zhu L et al. (2009) Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60: 1472-1483. doi:10.1002/art.24499. PubMed: 19404966.
|
| [34] | Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34: 149-162. doi:10.1016/j.immuni.2011.02.012. PubMed: 21349428.
|
| [35] | Inoue D, Numasaki M, Watanabe M, Kubo H, Sasaki T et al. (2006) IL-17A promotes the growth of airway epithelial cells through ERK-dependent signaling pathway. Biochem Biophys Res Commun 347: 852-858. doi:10.1016/j.bbrc.2006.06.137. PubMed: 16859642.
|
| [36] | Zhou Y, Toh ML, Zrioual S, Miossec P (2007) IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine 38: 157-164. doi:10.1016/j.cyto.2007.06.002. PubMed: 17644350.
|
| [37] | Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T (2012) Interleukin (IL)-17A synergistically enhances CC chemokine ligand 20 production in IL-1beta-stimulated human gingival fibroblasts. Hum Immunol 73: 26-30. doi:10.1016/j.humimm.2011.10.004. PubMed: 22019504.
|
